Descripción del proyecto
Optimización de la hipertermia como tratamiento antineoplásico
Aumentar la temperatura de los tumores hasta 40-44 °C —un proceso conocido como hipertermia— se está convirtiendo en un atractivo tratamiento antineoplásico que puede utilizarse para mejorar la eficacia de la radioterapia o la quimioterapia. El objetivo principal del proyecto HYPERBOOST, financiado con fondos europeos, es seguir mejorando la eficacia y la sinergia de la hipertermia mediante la determinación y aplicación de los niveles óptimos de temperatura y la sincronización óptima con otras modalidades en diferentes tipos de tumores. Los investigadores del proyecto estudiarán los mecanismos responsables del efecto terapéutico de la hipertermia mediante un método interdisciplinario que combina la biología, la física y la oncología. El conocimiento generado y las herramientas prácticas desarrolladas prepararán el camino para un tratamiento personalizado con hipertermia con mejores resultados clínicos.
Objetivo
Hyperthermia (HT), heating tumors to temperatures of 40-44°C, is an oncological treatment used in combination with
radiotherapy (RT) and chemotherapy to enhance their efficacy. Clinical effectiveness of HT has been demonstrated in
randomised studies and HT is currently applied for many clinical indications, like cervical cancer and recurrent breast cancer.
Clinical results can be further improved as application of HT with well-controlled tumor temperatures and optimal timing and
sequence realising full synergy of RT+HT is challenging. Optimal HT delivery requires accurate planning, moreover
preclinical research has shown that many mechanisms are responsible for the therapeutic effect of HT, all presumably with a
different temperature-effect relationship and with different optimal timing between RT and HT. Optimisation of clinical RT+HT
treatments therefore requires a quantum leap in understanding and in clinical application.
Scientific objective of this multidisciplinary project with contributions from all sectors and disciplines (biology, physics and
oncology) is to combine training and research into the synergistic molecular mechanisms responsible for the therapeutic
effect of HT on RT with the development of a versatile and innovative planning platform which utilises biological knowledge
to achieve optimal patient-specific treatment delivery and ultimately application in a clinical registration study in a network of
European centres implementing this treatment planning software to ensure optimal treatment delivery.
This ground-breaking and multidisciplinary project with contributions from biology, physics and oncology will create a
versatile and innovative planning platform, enhance fundamental knowledge and create practical tools to achieve
personalised treatment, thereby augmenting treatment delivery and clinical results. The projects will also educate 15 highly
skilled professionals capable of addressing and solving complex oncological issues.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
1081 HV Amsterdam
Países Bajos